Aldurazyme IV 2.9mg, containing Laronidase (genetically recombinant), is manufactured by Sanofi. This injectable drug, with YJ code 3959411A1020 and standard 2.9mg x 5mL x 1 bottle, is an enzyme replacement therapy for Mucopolysaccharidosis I (MPS I), including Hurler and Hurler-Scheie forms.
Aldurazyme IV 2.9mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).